Markets

Insider Trading

Hedge Funds

Retirement

Opinion

11 Cheap Small-Cap Stocks to Buy Before the Next Breakout

In this piece, we will take a look at 11 cheap small cap stocks to buy before the next breakout. If you want to skip out on an introduction to small cap stocks and the latest events in the stock market, then take a look at 5 Cheap Small-Cap Stocks to Buy Before the Next Breakout.

Different sectors of the stock market react differently to economic indicators and offer different kinds of returns. Large cap stocks such as Apple Inc. (NASDAQ:AAPL) and Meta Platforms, Inc. (NASDAQ:META) are better suited for times of turmoil as their heft and size weather serious downturns in the market. However, consumer defensive stocks such as Walmart Inc. (NYSE:WMT) outpace the mega cap technology stocks in ‘defending’ against share losses. On the flip side, small cap stocks typically fall significantly if the economic outlook is dour. This is because these firms have relatively smaller markets and are not able to hedge effectively against significant drops in consumer spending. Yet, as the condition improves, what goes down can go up, and small caps can lead their mega cap peers when it comes to returns.

Right now, investors in American stocks are watching the Federal Reserve with eagle eyes. While the central bank has signaled that today’s economic climate is quite different from last year, the fact that the U.S. economy has remained resilient and inflation has taken longer than expected to come down has still left some unease among investors. However, the close of August had some good news for investors. This came in the form of job openings, which measure the state of the labor market – one of the Fed’s most crucially watched metrics for its interest rate decisions.

The Labor Department’s Job Openings and Labor Turnover Survey (JOLTS) showed that job openings in July dropped by 338,000 to 8.83 million which was significantly lower than what economists polled by multiple news media outlets were expecting. For stocks, this is a bullish indicator since it shows that the job market is slowing down. It indicates that firms are hiring less aggressively than before and can reduce the compensation offered to new employees as well for a domino effect towards reducing inflation. The job openings rate further bolsters this conclusion as it dropped by 0.2% to sit at 5.3% for June.

Additionally, workers are also worried about a slowing economy as resignations also slowed down in July. They stood at 3.5 million in July which marked a 29 month low. Markets, which had dropped earlier this month in a wave of speculative selling improved after the JOLTS report. The S&P500 index was up 1.23% at the time of writing, while the NASDAQ 100,  the NASDAQ Composite, and the Dow Jones Industrial Average (DJIA) were up by 1.91%, 1.63%, and 0.68%, respectively.

Reaction in the small cap segment was roughly at par with the other indexes as the Russell 2000 and Russell 3000 stock indexes gained 1.28% and 1.20%, respectively. This 0.8% difference in the gains between the two underscores a crucial benefit of investing in small cap stocks as well. The logic in favor of small cap investing states that the smaller the stock, the more it can gain in percentage terms and the Russell 2000’s gains support this point of view since it is made of the 2000 smallest stocks in the Russell 3000 index.

A cautious turnaround in America’s economic outlook also appears to be influencing the optimism about the prospects of small cap investing. At least that’s what analysts at Bank of America Corporation (NYSE:BAC) believe. In a freshly released report, they have selected some top small cap stocks that can benefit from an economic recovery. The list includes firms from the biotechnology, energy, and industrial sectors, with some of the names being Northern Oil and Gas (NOG), Chord Electronics (NASDAQ:CHRD), Merus N.V. (NASDAQ:MRUS), MagnaChip Semiconductor Corporation (NYSE:MX), and Algoma Steel Group Inc. (NASDAQ:ASTL). In fact, interest in the small cap sector has actually started to pique as of late, with a report from July showing that flows in small cap stocks picking up in July and leading Bank of America to comment that a “potential” for a rally was present due to earlier bearish trends.

This sentiment is echoed by Chuck Royce’s Royce Investment Partners which shared in a recent blog post:

Yet we are optimistic both in spite of the relative disadvantage of small-caps and, in some ways, because of it.

First, significant multiple compression has occurred over the last several months among small caps, particularly small-cap value stocks. The result is that valuations looked highly favorable for the Russell 2000, on both an absolute basis and relative to the Russell 1000, where they remain close to a 20-year low, based on our preferred valuation metric, enterprise value over earnings before interest & taxes (“EV/EBIT”). Unsurprisingly in light of how it has recently lagged growth, the Russell 2000 Value Index finished June much more attractively valued than the Russell 2000 Growth Index, based on that same EV/EBIT metric. It is also worth noting that concerns about elevated valuations in the overall market have played out in an inflationary climate with rising interest rates and widespread anxiety that the economy is about to slip into a recession. We suspect that these concerns will continue to recede as economic news continues to skew more positively. Of course, we are more focused on the absolute valuations of individual companies, which in many instances look appealingly inexpensive to us. The average stock in the Russell 2000 was -28% off its 52-week high at the end of June, which gives some sense of the opportunity set that exists within small cap—and with it, the potential for improved performance going forward. Our expectation is that this potential will be realized over the next few years.

For some of Royce Investment’s stock picks during the first quarter, you can check out Chuck Royce Portfolio, Performance and Net Worth.

With these details in mind, we decided to take a look at some small cap stocks to buy before a potential breakout out of which some top picks are uniQure N.V. (NASDAQ:QURE), Aclaris Therapeutics, Inc. (NASDAQ:ACRS), and AbCellera Biologics Inc. (NASDAQ:ABCL).

Our Methodology

To compile our list of the cheap small cap stocks to buy before a breakout we made a list of firms whose shares trade below $10 and with analyst recommendations of Buy or better. To account for a potential breakout, only those stocks with the highest share price upside based on analyst average price targets were selected. The list was then further refined to account for hedge fund sentiment, as the stocks with the stocks with highest hedge fund number of hedge fund investors during this year’s second quarter were selected for the final collection

11 Cheap Small-Cap Stocks to Buy Before the Next Breakout

11. Repare Therapeutics Inc. (NASDAQ:RPTX)

Number of Hedge Fund Investors In Q2 2023: 14

Latest Share Price: $9.81

Repare Therapeutics Inc. (NASDAQ:RPTX) is a Canadian biotechnology firm that develops cancer treatments using gene editing technologies. The firm’s average analyst share price target sits at $27, for a sizeable upside over the current share price. Its second quarter earnings report saw the company beat analyst EPS estimates, and a proof of concept trial for a tumor treatment also demonstrated favorable results in June.

For the quarter ending in June 2023, 14 out of the 910 hedge funds profiled by Insider Monkey had held a stake in Repare Therapeutics Inc. (NASDAQ:RPTX). Out of these, the firm’s biggest investor is Mark Lampert’s Biotechnology Value Fund / BVF Inc since it owns 8.2 million shares that are worth $87.7 million.

10. Aadi Bioscience, Inc. (NASDAQ:AADI)

Number of Hedge Fund Investors In Q2 2023: 14

Latest Share Price: $6.76

Aadi Bioscience, Inc. (NASDAQ:AADI) is another biotechnology company developing cancer treatments. The stock is rated Strong Buy on average and the average share price target is $35. Aadi Bioscience, Inc. (NASDAQ:AADI)’s second quarter results saw it report $6.2 million in revenue for a substantial growth over the year ago quarter’s $3.4 million.

During this year’s second quarter, 14 out of the 910 hedge funds researched by Insider Monkey had invested in Aadi Bioscience, Inc. (NASDAQ:AADI). Along with uniQure N.V. (NASDAQ:QURE), Aclaris Therapeutics, Inc. (NASDAQ:ACRS), and AbCellera Biologics Inc. (NASDAQ:ABCL) it is a small cap stock that might be worth buying before the next breakout.

9. The Joint Corp. (NASDAQ:JYNT)

Number of Hedge Fund Investors In Q2 2023: 16

Latest Share Price: $9.61

The Joint Corp. (NASDAQ:JYNT) is a chiropractic services provider with hundreds of clinics all over America. Its average analyst share price target is $31. However, the shares dipped in August after the firm delayed the filing of its second quarter results despite marking strong revenue growth.

Insider Monkey’s June quarter of 2023 survey of 910 hedge funds revealed 16 The Joint Corp. (NASDAQ:JYNT) investors. The firm’s largest hedge fund shareholder is Gregory Bylinsky and Jefferson Gramm’s Bandera Partners due to its $35.7 million stake.

8. Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)

Number of Hedge Fund Investors In Q2 2023: 17

Latest Share Price: $8.89

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) is a biotechnology firm that develops treatments for skin diseases. It’s another stock that is rated Strong Buy on average and the average share price target is a whopping $41.88.

Insider Monkey’s Q2 2023 research of 910 hedge fund holdings outlined that 17 had bought a stake in the company. Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)’s biggest stakeholder is David Rosen’s Rubric Capital Management since it owns $46 million worth of shares.

7. Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Number of Hedge Fund Investors In Q2 2023: 18

Latest Share Price: $8.59

Nurix Therapeutics, Inc. (NASDAQ:NRIX) is an American firm making treatments for lymphoma, tumors, and other cancers. Despite a worrying cash burn rate, the firm’s revenue is actually growing, with the second quarter results showing $30.7 million in net sales which more than doubled over the year ago quarter’s $11 million.

After scouring through 910 hedge funds for their second quarter of 2023 shareholdings, Insider Monkey discovered that 18 had invested in Nurix Therapeutics, Inc. (NASDAQ:NRIX). Julian Baker and Felix Baker’s Baker Bros. Advisors is the company’s largest stakeholder, owning 3.8 million shares that are worth $38.7 million.

6. Edgewise Therapeutics, Inc. (NASDAQ:EWTX)

Number of Hedge Fund Investors In Q2 2023: 19

Latest Share Price: $7.00

Edgewise Therapeutics, Inc. (NASDAQ:EWTX) focuses its efforts on developing treatments for diseases of the heart and the muscular system. While the shares currently trade for $7, analysts have penned in a massive upside through an average share price target of $27.

19 out of the 910 hedge funds part of Insider Monkey’s Q2 2023 database have bought the firm’s shares. Edgewise Therapeutics, Inc. (NASDAQ:EWTX)’s biggest investor is Samuel Isaly’s OrbiMed Advisors since it owns a stake worth $112 million.

uniQure N.V. (NASDAQ:QURE), Edgewise Therapeutics, Inc. (NASDAQ:EWTX), Aclaris Therapeutics, Inc. (NASDAQ:ACRS), and AbCellera Biologics Inc. (NASDAQ:ABCL) are some cheap small cap stocks with positive indicators.

Click to continue reading and see 5 Cheap Small-Cap Stocks to Buy Before the Next Breakout.

Suggested Articles:

Disclosure: None. 11 Cheap Small-Cap Stocks to Buy Before the Next Breakout is originally published on Insider Monkey.

AI Fire Sale: Insider Monkey’s #1 AI Stock Pick Is On A Steep Discount

Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal!

The whispers are turning into roars.

Artificial intelligence isn’t science fiction anymore.

It’s the revolution reshaping every industry on the planet.

From driverless cars to medical breakthroughs, AI is on the cusp of a global explosion, and savvy investors stand to reap the rewards.

Here’s why this is the prime moment to jump on the AI bandwagon:

Exponential Growth on the Horizon: Forget linear growth – AI is poised for a hockey stick trajectory.

Imagine every sector, from healthcare to finance, infused with superhuman intelligence.

We’re talking disease prediction, hyper-personalized marketing, and automated logistics that streamline everything.

This isn’t a maybe – it’s an inevitability.

Early investors will be the ones positioned to ride the wave of this technological tsunami.

Ground Floor Opportunity: Remember the early days of the internet?

Those who saw the potential of tech giants back then are sitting pretty today.

AI is at a similar inflection point.

We’re not talking about established players – we’re talking about nimble startups with groundbreaking ideas and the potential to become the next Google or Amazon.

This is your chance to get in before the rockets take off!

Disruption is the New Name of the Game: Let’s face it, complacency breeds stagnation.

AI is the ultimate disruptor, and it’s shaking the foundations of traditional industries.

The companies that embrace AI will thrive, while the dinosaurs clinging to outdated methods will be left in the dust.

As an investor, you want to be on the side of the winners, and AI is the winning ticket.

The Talent Pool is Overflowing: The world’s brightest minds are flocking to AI.

From computer scientists to mathematicians, the next generation of innovators is pouring its energy into this field.

This influx of talent guarantees a constant stream of groundbreaking ideas and rapid advancements.

By investing in AI, you’re essentially backing the future.

The future is powered by artificial intelligence, and the time to invest is NOW.

Don’t be a spectator in this technological revolution.

Dive into the AI gold rush and watch your portfolio soar alongside the brightest minds of our generation.

This isn’t just about making money – it’s about being part of the future.

So, buckle up and get ready for the ride of your investment life!

Act Now and Unlock a Potential 10,000% Return: This AI Stock is a Diamond in the Rough (But Our Help is Key!)

The AI revolution is upon us, and savvy investors stand to make a fortune.

But with so many choices, how do you find the hidden gem – the company poised for explosive growth?

That’s where our expertise comes in.

We’ve got the answer, but there’s a twist…

Imagine an AI company so groundbreaking, so far ahead of the curve, that even if its stock price quadrupled today, it would still be considered ridiculously cheap.

That’s the potential you’re looking at. This isn’t just about a decent return – we’re talking about a 10,000% gain over the next decade!

Our research team has identified a hidden gem – an AI company with cutting-edge technology, massive potential, and a current stock price that screams opportunity.

This company boasts the most advanced technology in the AI sector, putting them leagues ahead of competitors.

It’s like having a race car on a go-kart track.

They have a strong possibility of cornering entire markets, becoming the undisputed leader in their field.

Here’s the catch (it’s a good one): To uncover this sleeping giant, you’ll need our exclusive intel.

We want to make sure none of our valued readers miss out on this groundbreaking opportunity!

That’s why we’re slashing the price of our Premium Readership Newsletter by a whopping 70%.

For a ridiculously low price of just $29, you can unlock a year’s worth of in-depth investment research and exclusive insights – that’s less than a single restaurant meal!

Here’s why this is a deal you can’t afford to pass up:

• Access to our Detailed Report on this Game-Changing AI Stock: Our in-depth report dives deep into our #1 AI stock’s groundbreaking technology and massive growth potential.

• 11 New Issues of Our Premium Readership Newsletter: You will also receive 11 new issues and at least one new stock pick per month from our monthly newsletter’s portfolio over the next 12 months. These stocks are handpicked by our research director, Dr. Inan Dogan.

• One free upcoming issue of our 70+ page Quarterly Newsletter: A value of $149

• Bonus Reports: Premium access to members-only fund manager video interviews

• Ad-Free Browsing: Enjoy a year of investment research free from distracting banner and pop-up ads, allowing you to focus on uncovering the next big opportunity.

• 30-Day Money-Back Guarantee:  If you’re not absolutely satisfied with our service, we’ll provide a full refund within 30 days, no questions asked.

 

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

1. Head over to our website and subscribe to our Premium Readership Newsletter for just $29.

2. Enjoy a year of ad-free browsing, exclusive access to our in-depth report on the revolutionary AI company, and the upcoming issues of our Premium Readership Newsletter over the next 12 months.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!


No worries about auto-renewals! Our 30-Day Money-Back Guarantee applies whether you’re joining us for the first time or renewing your subscription a year later!

A New Dawn is Coming to U.S. Stocks

I work for one of the largest independent financial publishers in the world – representing over 1 million people in 148 countries.

We’re independently funding today’s broadcast to address something on the mind of every investor in America right now…

Should I put my money in Artificial Intelligence?

Here to answer that for us… and give away his No. 1 free AI recommendation… is 50-year Wall Street titan, Marc Chaikin.

Marc’s been a trader, stockbroker, and analyst. He was the head of the options department at a major brokerage firm and is a sought-after expert for CNBC, Fox Business, Barron’s, and Yahoo! Finance…

But what Marc’s most known for is his award-winning stock-rating system. Which determines whether a stock could shoot sky-high in the next three to six months… or come crashing down.

That’s why Marc’s work appears in every Bloomberg and Reuters terminal on the planet…

And is still used by hundreds of banks, hedge funds, and brokerages to track the billions of dollars flowing in and out of stocks each day.

He’s used this system to survive nine bear markets… create three new indices for the Nasdaq… and even predict the brutal bear market of 2022, 90 days in advance.

Click to continue reading…